narvo vexar
MaxCyte (MXCT) lost over 10% on Tuesday after announcing a cash and stock deal worth $151.8M to acquire Akron BioProducts, a Florida-based provider of materials and manufacturing services to the cell and gene therapy industry.
As part of the deal, the cell